Therefore, future work will focus on using gene editing technology to construct a p53 mutation model to clarify the necessity, develop targeted inhibitors to evaluate the therapeutic potential, and use single-cell sequencing to analyze the spatiotemporal interaction network between tumor cells and the immune microenvironment. The gene discussed is TP53; the disease is neoplasm.